SVB Leerink analyst Daniel Grosslight finds Livongo Health's 2.8M share offering a "bit of a surprise" since the initial public offering lockup does not expire until January 20. However, the company's current valuation "presents a compelling buying opportunity," Grosslight told investors last night in a research note. The analyst remains convinced that Livongo has built one of the "most robust" digital chronic care platforms and has a "long growth runway" ahead. He recommends accumulating the shares at these levels and keeps an Outperform rating on the name with a $50 price target.